Chronic posttransfusion non-A, non-B hepatitis and autoimmune chronic active hepatitis-aspects on treatment, prognosis and relation to hepatitis C virus.
Schvarcz
R
R
Department of Infectious Karolinska Institute, Roslagstull Hospital, Stockholm, Sweden.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000096:biosynthesis / Q000097:blood; D006526:Hepatitis C / Q000473:pathology / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D006801:Humans; D007165:Immunosuppression Therapy; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D015995:Prevalence; D011379:Prognosis; D011994:Recombinant Proteins; D065227:Transfusion Reaction; D016896:Treatment Outcome
D006508:Hepatitis Antibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011239:Prednisolone